IL2 and neoplasm: Tumor-specific synNotch receptor engineered T cells based on the synNotch pathway can independently of T cell activation, rely on bypass signaling pathways to achieve IL-2 secretion, thereby enhancing T cell proliferation and effects while reducing potential cell toxicity risks [252].